Clinical Trial Update: A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating HRS-1893 for heart failure with preserved ejection fraction, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• HRS-1893

Snippet

Sponsor: Shandong Suncadia Medicine Co., Ltd. | Conditions: Heart Failure With Preserved Ejection Fraction | Phase 2 | Status: NOT_YET_RECRUITING